TOP > 外国特許検索 > PEPTIDE, POLYNUCLEOTIDE, VECTOR, TRANSFORMANT, NFκB INHIBITOR, AND THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH ACCELERATED NFκB ACTIVITY

PEPTIDE, POLYNUCLEOTIDE, VECTOR, TRANSFORMANT, NFκB INHIBITOR, AND THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH ACCELERATED NFκB ACTIVITY 新技術説明会

外国特許コード F160008892
整理番号 (S2015-0250-N0)
掲載日 2016年10月25日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2015JP085286
国際公開番号 WO 2016098838
国際出願日 平成27年12月16日(2015.12.16)
国際公開日 平成28年6月23日(2016.6.23)
優先権データ
  • 特願2014-257827 (2014.12.19) JP
発明の名称 (英語) PEPTIDE, POLYNUCLEOTIDE, VECTOR, TRANSFORMANT, NFκB INHIBITOR, AND THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH ACCELERATED NFκB ACTIVITY 新技術説明会
発明の概要(英語) This peptide has an NFκB inhibitory effect and is any one of the following peptides: (a) a peptide comprising any amino acid sequence from SEQ ID NOs: 1-5; (b) a peptide having an NFκB inhibitory effect and comprising any amino acid sequence from SEQ ID NOs: 1-5, wherein one or a plurality of amino acid residues having been replaced, deleted and/or added; (c) a peptide having an NFκB inhibitory effect and comprising an amino acid sequence that is at least 80% homologous with any amino acid sequence from SEQ ID NOs: 1-5; (d) a peptide in which a cell-penetrating peptide is fused with any peptide selected from (a)-(c); and (e) a peptide in which a Met residue, a MetAla residue or an Ala residue is added to the N terminal of any peptide selected from (a)-(d).
特許請求の範囲(英語) [claim1]
1. It possesses NFkB obstruction action, description below (a) the - (e) from in each case is chosen the peptide of 1 kinds:
(A) Either of the SEQ ID NO 1-5 the peptide which consists of one amino acid arrangement,
(B) The peptide where 1 or several amino acid residues substitute either of the SEQ ID NO 1-5 in one, deficiency, and/or consist of the amino acid arrangement which is added, at the same time, possess NFkB obstruction action,
(C) The peptide which consists of the amino acid arrangement which possesses homology of 80% or more, either of the SEQ ID NO 1-5 vis-a-vis one amino acid arrangement at the same time, possesses NFkB obstruction action,
(D) The description above (a) the - (c) from in each case is chosen the peptide where membrane transmitted peptide is fused to the peptide of 1 kinds,
(E) The description above (a) the - (d) from in each case is chosen the peptide where the Met residue, the MetAla residue or the Ala residue are added to the N end of the peptide of 1 kinds.
[claim2]
2. It is the peptide where the description above (b) peptide, 1 -4 the amino acid residue substitutes SEQ ID NO in 1 or 2, deficiency, and/or consists of the amino acid arrangement which is added, at the same time, possesses NFkB obstruction action, in claim 1 the peptide of statement.
[claim3]
3. It is the peptide where the description above (b) peptide, 1 or 2 amino acid residues substitutes either of the SEQ ID NO 3-5 in one, deficiency, and/or consists of the amino acid arrangement which is added, at the same time, possesses NFkB obstruction action, in claim 1 the peptide of statement.
[claim4]
4. The description above (d) peptide, the description above (a) the - (c) from in each case is chosen is the peptide where membrane transmitted peptide is fused to C end of the peptide of 1 kinds, either of claim 1- claim 3 in 1 sections the peptide of statement.
[claim5]
5. Either of claim 1- claim 4 the NFkB inhibiter which includes the peptide of statement in 1 sections as the active ingredient.
[claim6]
6. Either of claim 1- claim 4 NFkB which includes the peptide of statement in 1 sections as the active ingredient *** the remedy medicine of the Shin characteristic disease.
[claim7]
7. The description above NFkB *** the Shin characteristic disease is the inflammation characteristic disease, in claim 6 NFkB of statement *** the remedy medicine of the Shin characteristic disease.
[claim8]
8. Either of claim 1- claim 4 in 1 sections the polynucleotide which the peptide of statement the cord/code is done.
[claim9]
9. The vector which includes the polynucleotide of statement in claim 8.
[claim10]
10. The transformant where the vector of statement is introduced into claim 9.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • ST. MARIANNA UNIVERSITY SCHOOL OF MEDICINE
  • 発明者(英語)
  • OKAMOTO KAZUKI
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
※ 技術移転のお問い合わせはMPO㈱でも結構です。TEL:044-979-1631 FAX:044-979-1632 Mail:info@mpoinc.Co.jp WEB:http://www.mpoinc.co.jp

PAGE TOP

close
close
close
close
close
close